ANSAcom – In collaboration with Johnson & Johnson Innovative Medicine
An investment of 580 million euros over the next five years, of which 125 million euros will support an increase of over 25% in the production capacity of the Latina plant to support innovative projects under development and new production technologies. It is the commitment in Italy of Johnson & Johnson Innovative Medicine, announced today, which is part of a strategic plan which envisaged a growth in investments in Italy of 9.2% each year for the period 2019-2023, three times higher than the pharmaceutical sector average, according to a new study by The European House – Ambrosetti. A focus on Research & Development for a total of almost 50 million euros in Italy (+11.7% every year since 2019), which includes 114 clinical studies, 993 research centers in Italy and access to treatments for more than 5,000 patients.
The projects announced include the Flex Line, to more efficiently manage the packaging of small production batches and a new continuous production line that will reduce the total end-to-end production time and allow medicines to reach patients more quickly . The Latina site, in particular, represents an important part of Johnson & Johnson’s global supply chain: it produces more than four billion tablets a year, for around 30 different products, and 97% of production is exported around the world.
“The plant is experiencing a significant evolution, we are strengthening our capabilities to serve a greater number of patients with innovative products – explains Jorge Lopez, General Manager of the Johnson & Johnson plant in Latina – It has been recognized as a 4IR (Industry 4.0) site by the World Economic Forum thanks to our commitment to innovation and sustainability”. The goal is to support “the growth of the current portfolio of medicines and our pipeline of innovative solutions – declares Oladapo Ajayi, Vice President, Innovative Medicine Supply Chain at Johnson & Johnson – which will allow us to continue to provide products to millions of patients all over the world.”
For Mario Sturion, Managing Director of Johnson & Johnson Innovative Medicine Italia, the commitment is to “increase the attractiveness and competitiveness of the country, strengthening research and excellent pharmaceutical production. We trust – he concludes – that innovation will continue to be welcomed, that the ecosystem of clinical trials will improve and that the constructive dialogue between institutions and industry – already started by the Government – will continue and remain active”.
ANSAcom – In collaboration with Johnson & Johnson Innovative Medicine
